Granules India to raise funds worth Rs 500 crores through QIP
Granules India Limited, a leading pharmaceutical company has decided to give the approval to raise funds amounting to Rs 500 crores by an issue of equity shares through a Qualified Institutions Placements, subject to the approval of shareholders, as per BSE filing. Read More
Poly Medicure plans to launch blood banking products
Poly Medicure, a leading manufacturer of medical devices on Thursday informed that the company is planning to undertake expansion plans in Faridabad and aims to launch blood banking products, reported a leading business news channel. Read More
Biocon receives 8 observations from US FDA
Biocon on Wednesday said it has received US FDA observations on Form 483 for its Bengaluru facility. According to a Biocon spokesperson the observations on Form 483 is a standard outcome of any audit. Read More
Marksans Pharma’s Goa plant approved by UK MHRA
Mumbai headquartered, Marksans Pharma in its filling to the exchanges said that the company’s goa plant has been approved by UK Medicines and Healthcare Products Regulatory Agency (UK MHRA) and can start supplying all drugs to the UK. Read More
Natco launches Pomalid; first generic version of pomalidomide capsules in India
Natco Pharma Limited on Wednesday, 10 May 2017, in its BSE filing said that it has launched a generic version of pomalidomide 1 mg, 2 mg, and 4 mg capsules in India. Read More
Aarey Drugs receives first commercial export order
Aarey Drugs and Pharmaceuticals Limited, a leading pharmaceutical company on Tuesday informed about receiving the first commercial export order for 20 metric tonnes of Thiobromine from Germany. The order will be executed by 30th June 2017, as per BSE filing. Read More
Natco Pharma unveils generic hepatitis C drug in India
Natco Pharma Limited, on Monday, 08 May 2017, announced that it has launched a generic version of sofosbuvir 400 mg / velpatasvir 100 mg fixed dose combination in India. Read More
Disclaimer: The contents herein is specifically prepared by ‘Dalal Street Investment Journal’, and is for your information & personal consumption only. India Infoline Limited or Dalal Street Investment Journal do not guarantee the accuracy, correctness, completeness or reliability of information contained herein and shall not be held responsible.
- Save upto Rs.2.67 lakh with Pradhan Mantri Awas Yojana ...Know more
- Now Save Rs.3150 on your Demat Account ...Click here
- Now get IIFL Personal Loan in just 8* hours...APPLY NOW!
- Get the most detailed result analysis on the web - Real Fast!
- Actionable & Award-Winning Research on 500 Listed Indian Companies.